Seagen Highlights First Solid Tumor Data for an ADCETRIS Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Seagen Inc. (NASDAQ: SGEN) today announced the first presentation of data evaluating ADCETRIS® (brentuximab vedotin) in combination with an anti-PD-1 checkpoint inhibitor in non-small cell lung cancer (NSCLC) and melanoma, and…

Read MoreSeagen Highlights First Solid Tumor Data for an ADCETRIS Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Roche announces EMBARK trial in Duchenne muscular dystrophy did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints

Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints Roche (SIX: RO, ROG; OTCQX:…

Read MoreRoche announces EMBARK trial in Duchenne muscular dystrophy did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy Novartis today announced positive topline results from the interim analysis…

Read MoreNovartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy
Epredia

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate Merck, a leading science and technology company, today announced a strategic collaboration with…

Read MoreMerck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate

Phase III RUBY trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer

Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer GSK plc today announced positive headline results…

Read MorePhase III RUBY trial of Jemperli plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer